Next Article in Journal
The Effects of Vitamin D Supplementation on Pulmonary Function of Chronic Obstructive Pulmonary Disease Patients, before and after Clinical Trial
Next Article in Special Issue
Synergistic Anticancer Activities of Natural Substances in Human Hepatocellular Carcinoma
Previous Article in Journal / Special Issue
HBV Core Protein Enhances Cytokine Production
Article Menu

Export Article

Open AccessReview
Diseases 2015, 3(4), 221-252; doi:10.3390/diseases3040221

A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma

Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Stephen L. Chan
Received: 9 July 2015 / Revised: 15 September 2015 / Accepted: 21 September 2015 / Published: 29 September 2015
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
View Full-Text   |   Download PDF [2042 KB, uploaded 29 September 2015]   |  

Abstract

Hepatocellular carcinoma (HCC), the second leading cause of cancer deaths worldwide, is difficult to treat and highly lethal. Since HCC is predominantly diagnosed in patients with cirrhosis, treatment planning must consider both the severity of liver disease and tumor burden. To minimize the impact to the patient while treating the tumor, techniques have been developed to target HCC. Anatomical targeting by surgical resection or locoregional therapies is generally reserved for patients with preserved liver function and minimal to moderate tumor burden. Patients with decompensated cirrhosis and small tumors are optimal candidates for liver transplantation, which offers the best chance of long-term survival. Yet, only 20%–30% of patients have disease amenable to anatomical targeting. For the majority of patients with advanced HCC, chemotherapy is used to target the tumor biology. Despite these treatment options, the five-year survival of patients in the United States with HCC is only 16%. In this review we provide a comprehensive overview of current approaches to target HCC. We also discuss emerging diagnostic and prognostic biomarkers, novel therapeutic targets identified by recent genomic profiling studies, and potential applications of immunotherapy in the treatment of HCC. View Full-Text
Keywords: hepatocellular carcinoma; liver resection; liver transplantation; locoregional therapy; targeted therapies; molecular signatures; biomarkers; immunotherapy hepatocellular carcinoma; liver resection; liver transplantation; locoregional therapy; targeted therapies; molecular signatures; biomarkers; immunotherapy
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Faltermeier, C.; Busuttil, R.W.; Zarrinpar, A. A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases 2015, 3, 221-252.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top